IGFBP-4，总（大鼠和小鼠）ELISA-IGFBP-4, Total (Rat and Mouse) ELISA代理/参数/厂家-ELISA试剂盒-艾美捷科技有限公司

PRODUCT CENTER

ELISA试剂盒

产品中心

当前位置：首页 > 产品中心 > 免疫学产品 > ELISA试剂盒

中文名称: IGFBP-4，总（大鼠和小鼠）ELISA

英文名字: IGFBP-4, Total (Rat and Mouse) ELISA

供应商: Ansh Labs

产品货号: AL-1028

产品报价: ￥询价/96wellmicrotiter

产品说明书: 点击查看

购买方式: 90%产品中国有现货库存。银行转账、电汇、支票、现金，在线支付宝及网银支付，或直接与我们电话联系400-6800-868

产品新闻

背景资料: Insulin‐like growth factor‐binding protein‐4 is a member of the insulin‐like growth factor binding protein (IGFBP) family and encodes a protein with an IGFBP domain and a thyroglobulin type‐I domain. The cDNA for human IGFBP‐4 encodes a 258‐residue protein that is processed, by removal of the signal sequence, to a mature protein of 237 residues (25.6 kDa) with a single asparagine‐linked glycosylation site(1). Although various cell types when in culture secrete both glycosylated (28‐29 kDa) and nonglycosylated (24‐25 kDa) forms of IGFBP‐4, the nonglycosylated is typically the most abundant in normal human blood (2, 3).
n
n
n
nIGFBP‐4 is unique among the six IGFBPs in having two extra cysteine residues in the variable L‐domain and may be responsible for the distinctive biological functions of IGFBP‐4 (4). Although the exact functional role for serum IGFBP‐4 is not absolutely clear, in vitro studies have shown that IGFBP‐4 inhibits IGF activity in bone cells and other cell types. IGFBP‐4 has been reported to inhibit IGF‐I‐ and IGF‐II‐induced cell proliferation of embryonic chick calvaria cells and MC3T3‐E1 mouse osteoblasts (5, 6), IGF‐I‐ and IGF‐II stimulated DNA synthesis in a variety of cell types.(3)
n
n
n
nProteolysis is a major regulatory mechanism of IGFBP‐4 functions. An IGF dependent IGFBP‐4‐specific protease was first reported in the media conditioned by both human and sheep dermal fibroblasts. This protease was later identified as pregnancy‐associated plasma protein‐A (PAPP‐A). It was shown that recombinant PAPP‐A is an active protease able to cleave IGFBP‐4 at a single site, between M135/K136. IGFBP‐4 cleavage by PAPP‐A is possible only in case when IGFBP is complexed with IGF. PAPP‐A also cleaves IGFBP‐5 between S143/K144, but in this case the presence of IGF is not required.
n
n
n
nSeveral studies have shown that concentration of PAPP‐A in blood of patients with acute coronary syndrome (ACS) is higher than in blood of patients with stable coronary artery disease or control subjects. PAPP‐A has been suggested as a marker of cardiovascular diseases associated with coronary artery blood clotting, such as unstable angina and myocardial infarction (MI) (7‐14). It was hypothesized that in atherosclerotic plaques PAPP‐A expressed by activated smooth muscles cells could function as an active enzyme cleaving IGFBP‐4 complexed with IGF, thus enhancing IGF bioavailability. The IGF system might contribute to the atherosclerotic plaque development, destabilization, and rupture leading to acute coronary events (15). It was shown that IGFBP‐4 is expressed by different cells of tumor origin, such as lung adenocarcinoma, non‐small‐cell lung cancer, breast cancer, colon carcinoma, follicular thyroid carcinoma, gastric cancer, glioma, hepatoma, myeloma, neuroblastoma, osteosarcoma and prostate cancer. In vitro and in vivo studies suggest that IGFBP‐4 plays an important role in the growth regulation of a variety of tumors, possibly by inhibiting autocrine IGF actions. Regulation of IGF bioavailability may play a crucial role in tumor growth and development (13).
n
n
n
nThe measurements of IGFBP‐4 along with PAPP‐A enzyme activity could be of higher clinical value than just PAPP‐A measurements alone since PAPP‐A concentration in blood is affected by heparin injections. The concentration of human PAPP‐A, total human IGFBP‐4 and intact human IGFBP‐4 in human biological fluid can be measured accurately using immunoassay methods (picoPAPP‐A ELISA, AL‐101; Total IGFBP‐4 ELISA, AL‐126; and Intact IGFBP‐4 ELISA, AL‐128 respectively). Similarly, the concentration of mouse PAPP‐A and Intact mouse IGFBP‐4, Total mouse IGFBP‐4 in biological fluids can be measured accurately using mouse PAPP‐A ELISA, AL‐158; Intact Rat/Mouse IGFBP‐4 ELISA, AL‐1025; and Total Rat/Mouse IGFBP‐4 ELISA, AL‐1025.
n
n
n
nReferences:
n1. La Tour D, Mohan S, Linkhart T A, Baylink D J, Strong D D. Inhibitory insulin-like growth factor binding protein: cloning, complete sequence, and physiologic regulation. Mol Endocrinol. 1990; 4:1806-1814.
n2. Baxter R C, Martin J L. Binding proteins for the insulin-like growth factors: structure, regulation and function. Prog in Growth Factor Res. 1989; 1:49-68.
n3. Rechler M M., Insulin-like growth factor binding proteins. Vitam Horm. 1993; pp. 471-114.
n4. Zhou R, Diehl D, Hoeflich A, Lahm H, Wolf E., IGF-binding protein-4: biochemical characteristics and functional consequences. Journal of Endocrinology 2003; 178: 177-193.
n5. Mohan S, Bautista C, Wergedal J, Baylink D J. Isolation of an inhibitory insulin-like growth factor (IGF) binding protein from bone cell conditioned medium: a potential local regulator of IGF action. Proc Nat Acad Sci USA. 1989; 86:8338-8342.
n6. Mohan S, Nakao Y, Honda Y, et al., Studies on the molecular mechanisms by which insulin-like growth factor (IGF) binding protein-4 (IGFBP-4) and IGFBP-5 modulate IGF actions in bone cells. J Biol Chem. 1995; 270:20424-20431.
n7. Qin Q, Wittfooth S, Pettersson K. Measurement and clinical significance of circulating PAPP-A in ACS patients. Clin Chim Acta. 2007;380:59-67. 8. Iversen KK, Teisner AS, Teisner B, et al. Pregnancy Associated Plasma Protein A, a Novel, Quick, and Sensitive marker in ST-Elevation Myocardial Infarction. Am J Cardiol. 2008;101:1389-1394.
n9. Lund J, Qin Q, Ilva T, et al. Pregnancy-associated plasma protein A: A biomarker in acute ST-elevation myocardial infarction (STEMI). Annals of Medicine. 2006;38:221-228.
n10. Elesber AA, Lerman A, et al. Pregnancy associated plasma protein-A and risk stratification of patients presenting with chest pain in the emergency department. Int J Cardiol. 2007;117:365-369.
n11. Heeschen C, Dimmeler S, et al. Pregnancy-Associated Plasma Protein-A Levels in Patients With Acute Coronary Syndromes. JACC. 2005;45(2):229-237.
n12. Lund J, Qin Q, Ilva T, et al. Circulating Pregnancy-Associated Plasma Protein A Predeicts Outcome in Patients With Acute Coronary Syndrome but No Troponin I Elevation. Circulation. 2003;108:1924-1926.
n13. Bayes-Genis A, Conover CA, et al. Pregnancy-Associated Plasma Protein A as a Marker of Acute Coronary Syndromes. NEJM. 2001;345(14):1022-1029.

产品描述: The Total Rat/Mouse IGFBP‐4 enzyme linked immunosorbent assay (ELISA) kit provides materials for the quantitative measurement of IGFBP‐4 in rat and mouse samples.

产品特点

保存建议: Store at 2 to 8°C until expiration date.

其他: Ansh labs是开发和生产免疫检测试剂盒和定制生物技术检测产领创者，总部位于美国休斯敦，公司产品遍及全球80多个国家。公司于2011年成立，核心团队来自于Diagnostic system laboratory，专注于女性健康和激素检测领域近40年，拥有全球领先的核心技术，以及多年经验生物技术研发经验的科学家团队，产品覆盖生殖健康，高危妊娠，肿瘤，糖尿病等多个疾病领域，围绕最新的免疫分析技术，多种蛋白和单克隆抗体，如AMH，BMP-15, Follistatin, GDF-9, IGF-I, IGF-II, IGFBP-2, IGFBP-3, IGFBP-4, IGFBP-5, Inhibin Alpha, Inhibin ?A, Inhibin ?B, MBP, PAPP-A, PAPP-A2 and Vitamin D.等几十余种试剂产品，也同时涵盖小鼠，大鼠，狗，羊，牛等灵长类多个物种的独特的物种特异性的试剂。 Ansh labs 坐落于美国德克萨斯州，是目前世界上唯一能提供TGF-β超家族所有成员的检测公司，也是最早专注激素类产品研究和新型免疫检测技术的先驱者。优势产品涉及TGF-β super family、AMH/抑制素B(human/animal)、full panel IGFs、以及最完整的胰高血糖素系列。